Presbia PLC (LENS) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $14. Rodman & Renshaw advised their investors in a research report released on May 10, 2016.
Presbia PLC opened for trading at $3.49 and hit $3.5901 on the upside on Friday, eventually ending the session at $3.58, with a gain of 3.77% or 0.13 points. The heightened volatility saw the trading volume jump to 8,490 shares. Company has a market cap of $48 M.
In a different news, on Nov 30, 2015, Randy H Thurman (Executive Chairman) purchased 1,833 shares at $5.45 per share price. According to the SEC, on Nov 23, 2015, Zohar Loshitzer (Chief Bus. Development Officer) purchased 5,500 shares at $4.00 per share price. On Nov 20, 2015, Robert J Cresci (director) purchased 10,000 shares at $3.97 per share price, according to the Form-4 filing with the securities and exchange commission.
Presbia PLC is a development-stage ophthalmic device company. The Company has developed and is marketing an optical lens implant for treating presbyopia the age-related loss of the ability to focus on near objects. Its lens which it refers to as its microlens is a miniature lens designed to be surgically implanted in a patient’s eye for that patient’s ability to see objects at close distances. Its microlens procedure is performed using a 150 kilohertz femtosecond laser. In commercializing its solution it intends to focus those markets with a presence of refractive laser centers equipped with femtosecond lasers. The Presbia Flexivue Microlens is a solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser. It offers a solution for people to read common items such as newspapers restaurant menus cell phone messages and supermarket labels without glasses.